ARTIBAC

ARTIBAC develops new biotechnology-derived drugs against multidrug-resistant bacteria by integrating artificial-intelligence-guided discovery with experimental validation in a clinical, academic and industrial consortium based in Lombardy.

Role of our laboratory

Recombinant protein production, structural biology and experimental validation within an AI-enabled biotechnology drug-discovery programme targeting multidrug-resistant bacteria.

Project details

• Full title: New biotechnology drugs and artificial intelligence against multidrug-resistant bacteria (ARTIBAC)
• Funding agency: Regione Lombardia
• Programme: Collabora & Innova
• Project code: 6075011
• Total project funding: EUR 1’737’694.24 (funding to the laboratory: EUR 247’371.93)
• Project period: 2 January 2025 – 2 April 2027
• Institutions involved: ASST Fatebenefratelli Sacco (Italy), DATRIX S.p.A. (Italy), Fondazione Istituto Insubrico di Ricerca per la Vita (FIIRV, Italy), Fondazione Istituto Nazionale di Genetica Molecolare (INGM, Italy), Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano (Italy), University of Pavia (Italy)

Co-Investigator / Unit Coordinator

Federico Forneris

Permanent Staff – Armenise-Harvard Laboratory